New ALS Drug Shows Promise in Strength, Mobility Boost
Rickey Malloy (left), who receives tofersen treatment for SOD1-ALS at WashU Medicine, plays a round of golf with his wife, Jenny, and their son, Kash. Long-term use of tofersen, a new drug approved by the FDA for this rare genetic form of ALS, delays symptom progression and death and leads to stabilization or improvement in some, according to a study by WashU Medicine researchers and their collaborators. (Photo: Huy Mach/WashU Medicine)
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
